New Opportunities for Treatment and Prevention of Neurodegenerative Diseases With PTP1B Inhibitors

Future Medicinal ChemistryVol. 15, No. 16 CommentaryNew opportunities for treatment and prevention of neurodegenerative diseases with PTP1B inhibitorsDominika Kołodziej, Łukasz Sobczak & Krzysztof Z ŁączkowskiDominika Kołodziej *Author for correspondence: E-mail Address: d.kolodziej@doktorant.umk.plhttps://orcid.org/0000-0003-2906-0333Department of Chemical Technology and Pharmaceuticals, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, 85-089, Poland, Łukasz Sobczak https://orcid.org/0000-0003-1998-3783Hospital Pharmacy, Municipal Hospital in Bydgoszcz, Bydgoszcz, 85-826, PolandFaculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, 85-067, Poland & Krzysztof Z Łączkowski https://orcid.org/0000-0003-2107-2719Department of Chemical Technology and Pharmaceuticals, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, 85-089, PolandPublished Online:23 Aug 2023https://doi.org/10.4155/fmc-2023-0187AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: Alzheimer's diseaseamyotrophic lateral sclerosismultiple sclerosisneurodegenerative diseasesParkinson's diseasePTP1BReferences1. Gammon K. Neurodegenerative disease: brain windfall. Nature 515, 299–300 (2014).MedlineGoogle Scholar2. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293(5), 596–608 (2005).Medline CASGoogle Scholar3. Kuhlwilm L, Schönfeldt-Lecuona C, Gahr M, Connemann BJ, Keller F, Sartorius A. The neuroleptic malignant syndrome – a systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatr. Scand. 142(3), 233–241 (2020).Medline CASGoogle Scholar4. Solomon A, Turunen H, Ngandu T et al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol. 75(4), 462–470 (2018).MedlineGoogle Scholar5. Se Thoe E, Fauzi A, Tang YQ, Chamyuang S, Chia AYY. A review on advances of treatment modalities for Alzheimer's disease. Life Sci. 276, 119129 (2021).MedlineGoogle Scholar6. Liu R, Mathieu C, Berthelet J, Zhang W, Dupret J-M, Rodrigues Lima F. Human protein tyrosine phosphatase 1B (PTP1B): from structure to clinical inhibitor perspectives. Int. J. Mol. Sci. 23(13), 7027 (2022).Medline CASGoogle Scholar7. Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit. Care 10(1), 136–140 (2009).MedlineGoogle Scholar8. Castrioto A, Kistner A, Klinger H et al. Psychostimulant effect of levodopa: reversing sensitisation is possible. J. Neurol. Neurosurg. Psychiatry 84, 18–22 (2013).MedlineGoogle Scholar9. Moro E, Lozano AM, Pollak P et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov. Disord. 25, 578–586 (2010).MedlineGoogle Scholar10. Feng CW, Chen NF, Chan TF, Chen WF. Therapeutic role of protein tyrosine phosphatase 1B in Parkinson's disease via antineuroinflammation and neuroprotection in vitro and in vivo. Parkinsons Dis. 2020, 8814236 (2020).MedlineGoogle Scholar11. Paganoni S, Macklin EA, Hendrix S et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 383(10), 919–930 (2020).Medline CASGoogle Scholar12. Sun Y, Li X, Bedlack R. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. Expert Rev. Neurother. 23(1), 1–7 (2023).Medline CASGoogle Scholar13. Miller TM, Cudkowicz ME, Genge A et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387(12), 1099–1110 (2022).Medline CASGoogle Scholar14. Lee S, Kim S, Kang HY et al. The overexpression of TDP-43 in astrocytes causes neurodegeneration via a PTP1B-mediated inflammatory response. J. Neuroinflammation 17(1), 299 (2020).Medline CASGoogle Scholar15. Titcomb TJ, Bao W, Du Y, Liu B, Snetselaar LG, Wahls TL. Association of multiple sclerosis with risk of mortality among a nationally representative sample of adults in the United States. Mult. Scler. J. Exp. Transl. Clin. 8(2), 20552173221104009 (2022).Google Scholar16. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA 325(8), 765–779 (2021).Medline CASGoogle Scholar17. Hartung DM. Economics of multiple sclerosis disease-modifying therapies in the USA. Curr. Neurol. Neurosci. Rep. 21, 28 (2021).MedlineGoogle Scholar18. Tezuka K, Suzuki M, Sato R, Kawarada S, Terasaki T, Uchida Y. Activation of Annexin A2 signaling at the blood–brain barrier in a mouse model of multiple sclerosis. J. Neurochem. 160(6), 662–674 (2022).Medline CASGoogle Scholar19. de Boer EMJ, Orie VK, Williams T et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry 92, 86–95 (2021).Google Scholar20. Hussain H, Djurin T, Rodriguez J et al. Transactivation response DNA-binding protein of 43 (TDP-43) and glial cell roles in neurological disorders. Cureus 14(10), e30639 (2022).MedlineGoogle ScholarFiguresReferencesRelatedDetails Vol. 15, No. 16 STAY CONNECTED Metrics Downloaded 26 times History Received 29 June 2023 Accepted 1 August 2023 Published online 23 August 2023 Published in print August 2023 Information© 2023 Newlands PressKeywordsAlzheimer's diseaseamyotrophic lateral sclerosismultiple sclerosisneurodegenerative diseasesParkinson's diseasePTP1BAuthor contributionsD Kołodziej: conceptualization, investigation, methodology, writing (original draft, review and editing); Ł Sobczak: investigation, writing (review and editing); KZ Łączkowski: supervision, writing (review and editing).Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download